Soolantra and prescription azelaic acid are different topical treatment options for inflammatory lesions of rosacea in the United States. Soolantra contains ivermectin 1% in a prescription cream. U.S. prescription azelaic acid products used for rosacea include 15% gel and 15% foam. These are different active ingredients and formulations, not brand and generic versions of the same medicine. A useful comparison starts with the exact product label, the kind of rosacea symptoms being treated, and whether the product is a prescription medicine or a cosmetic skin-care preparation.
The distinction becomes important when a search result simply says “azelaic acid cream” or “azelaic acid for rosacea.” The U.S. label for Azelex 20% cream covers inflammatory acne, not an FDA-approved rosacea indication, while labeled azelaic acid 15% gel and foam products specifically address inflammatory papules and pustules of mild-to-moderate rosacea. Over-the-counter cosmetics containing azelaic acid should not be presented as therapeutically interchangeable with prescription rosacea products merely because they mention the same ingredient. Concentration and vehicle identify products; they do not alone predict which will work best for an individual.
This page compares prescription Soolantra with azelaic acid options from a U.S. product and treatment-choice perspective, including FDA indications, clinical evidence and practical pharmacy questions. For the branded ivermectin product itself, see Soolantra cream 1%. For a different active ingredient comparison, read Soolantra vs metronidazole. Decisions about treatment, a switch between active ingredients or a combination regimen require evaluation by a qualified clinician; no pharmacy listing or general comparison guarantees a clinical result.
Both active ingredients can be relevant to inflammatory rosacea, but the names of their preparations can be misleading. Soolantra is a specific brand of ivermectin cream 1%. Azelaic acid refers to an ingredient sold in different vehicles and concentrations, with labeling that can differ by product. A cream labeled 20% azelaic acid is not automatically the same kind of rosacea product as a 15% azelaic acid gel or foam. The comparison below separates U.S. prescription rosacea medications from other commonly encountered azelaic acid listings.
The table is a product-identity and regulatory comparison, not a recommended treatment sequence or an inventory report. Individual generic labels and current marketing status should be checked for the exact NDC or pharmacy listing. FDA approval does not guarantee that a particular seller stocks a product, and an online listing using the word “rosacea” does not establish that its claims match the official label.
| Product or product type | Active ingredient and form | U.S. labeling context | Access and comparison note |
|---|---|---|---|
| Soolantra cream 1% | Ivermectin 1%, topical cream | Inflammatory lesions of rosacea | Prescription; branded ivermectin product |
| Azelaic acid gel 15% (e.g., Finacea) | Azelaic acid 15%, topical gel | Inflammatory papules and pustules of mild-to-moderate rosacea | Prescription; compare exact gel label and product identity |
| Azelaic acid foam 15% (e.g., Finacea Foam) | Azelaic acid 15%, topical foam | Inflammatory papules and pustules of mild-to-moderate rosacea | Prescription; distinct foam vehicle, labeling and handling precautions |
| Azelex cream 20% | Azelaic acid 20%, topical cream | Mild-to-moderate inflammatory acne vulgaris | Prescription acne product; not FDA-labeled specifically for rosacea |
| Nonprescription cosmetic azelaic acid preparations | Variable cosmetic serums or creams | No FDA-approved rosacea drug indication based on cosmetic labeling alone | Do not infer equivalent drug performance or prescription-product status |
Ivermectin and azelaic acid are distinct chemical ingredients with different pharmacologic properties. Soolantra uses ivermectin in a 1% cream vehicle; 15% azelaic acid rosacea medicines place a different active ingredient in gel or foam vehicles. They are not interchangeable on a milligram-for-milligram basis, and a larger percentage on a package does not mean that one medicine is stronger or superior. The meaningful comparisons involve FDA-labeled indications, the formulation studied, clinical response measures, local tolerability and the practical needs of the person being treated.
Rosacea is not a single symptom. Inflammatory papules and pustules, persistent background redness, intermittent flushing, sensitive skin and eye symptoms may coexist but do not necessarily respond to the same intervention. The labels for these products focus on inflammatory lesions. Soolantra is indicated for inflammatory lesions of rosacea; azelaic acid 15% gel and foam are indicated for inflammatory papules and pustules of mild-to-moderate rosacea. Neither indication should be rewritten as a promise to remove facial vessels, permanently resolve flushing or cure every source of facial redness.
A shopper who sees Soolantra and generic ivermectin cream 1% as alternatives is considering the same active ingredient. That question belongs to the brand versus generic ivermectin cream comparison. Choosing between Soolantra and azelaic acid is a different clinical decision because it changes the active ingredient, not just the brand on the tube. A clinician should review symptoms, prior treatments and the diagnosis before making that change.
Azelaic acid 15% gel and 15% foam are prescription formulations with U.S. rosacea indications. A gel tube and a foam container may have different inactive ingredients, application instructions, packaging and precautions even when the ingredient concentration is the same. For example, the labeled 15% foam is an aerosol product with flammability precautions that do not apply identically to a gel tube. Pharmacy records should therefore identify the prescribed vehicle and concentration, rather than treating the ingredient name alone as a complete product description.
Azelex 20% cream introduces a separate question: its U.S. FDA indication is for mild-to-moderate inflammatory acne vulgaris. A clinician might discuss different topical uses in an individual clinical context, but that does not turn its labeled acne indication into a rosacea approval. In particular, it would be misleading to create a comparison table stating that all azelaic acid creams, gels, foams and cosmetic serums have the same official indication. The fact that some patients have both acne-like lesions and rosacea makes diagnostic precision more important, not less.
When comparing a Soolantra tube with an azelaic acid package, read the ingredient, concentration, exact dosage form, route and labeled indication. Ask which product was actually prescribed and whether the pharmacy is offering that exact formulation. A generic azelaic acid 15% gel is not the same product as a 20% cream, and a foam should not be substituted for a gel solely because both labels mention azelaic acid. The pharmacist or prescriber can explain whether a proposed change is appropriate under the prescription and state substitution rules.
Some U.S. retail and online skin-care listings promote azelaic acid in cosmetic serums, creams or combinations with other ingredients. Those products may be sold without a prescription, but OTC retail availability is not evidence that a product has undergone FDA drug review for inflammatory rosacea or that it is therapeutically equivalent to prescription azelaic acid gel 15%. A label that uses cosmetic language about texture or complexion is not interchangeable with a prescription drug label that identifies a defined medical indication.
Packaging claims such as “15% azelaic acid,” “dermatologist inspired,” “rosacea-friendly” or “professional strength” do not by themselves establish regulatory identity, clinical efficacy or generic equivalence. The percentage, vehicle, other ingredients and intended legal product category all matter. In addition, a marketplace listing may use the ingredient name broadly while leaving the exact product classification unclear. A buyer should not infer from an advertising headline that an unverified serum replaces prescribed Soolantra or a labeled azelaic acid 15% rosacea drug.
For a person exploring products because of sensitivity, cost or difficulty obtaining a prescription, it is more useful to clarify the diagnosis and ask a clinician or pharmacist what evidence supports the specific option. The decision is not simply “prescription versus cheap OTC.” A change in product category can change the evidence base, formulation and expectations. General skin-care measures may be discussed as supportive care, but they should not be presented as an equivalent medical treatment merely because a cosmetic contains the same ingredient family.
Both ivermectin cream 1% and azelaic acid 15% products have evidence supporting their roles in inflammatory rosacea, but not every comparative publication asks the same question. Trials that compare one medicine with its vehicle can establish efficacy against that control; they cannot automatically rank that medicine above every other available drug. Indirect comparisons across separate trials also depend on study populations, endpoints, treatment schedules and other assumptions. This is why a concise claim that “Soolantra always works better” or “azelaic acid is always stronger” would overstate the evidence.
Published long-term extension studies have included ivermectin 1% cream and azelaic acid 15% gel over an extended observation period. Those studies provide information about tolerability in that setting, but the extension design followed preceding trial assignments and was not equivalent to a fresh, fully blinded head-to-head efficacy trial in which all participants began their assigned active treatment at the same time. Adverse-event comparisons from that design should be interpreted with those limitations in mind rather than converted into a guaranteed prediction for an individual user.
Network meta-analyses have also compared these agents indirectly. Different analyses have used different included trials, formulations and outcomes, and may not produce the same apparent ranking. These methods are helpful for research context but cannot erase differences between 15% gel, 15% foam, 20% cream and the particular clinical target being measured. When discussing published results with a clinician, the useful questions are which exact formulations were evaluated, whether the outcome was inflammatory lesion reduction or another measure, and how relevant the participants were to the current diagnosis.
Prescription azelaic acid gel and foam can cause local application-site reactions such as burning, stinging, itching, dryness or irritation. Soolantra cream can also cause local irritation or burning. The likelihood and significance of these experiences cannot be predicted from the ingredient percentage alone, and trial adverse-event percentages should not be compared across unrelated studies as if they came from one controlled experiment. Vehicle choice, prior sensitivities, existing skin-barrier irritation and accompanying skin-care products can influence the discussion with a clinician.
The azelaic acid 15% foam label has special precautions for flammability because it is an aerosol formulation. Azelaic acid labels also include warnings about avoiding the eyes and mucous membranes; some labels discuss possible pigment changes and other precautions in particular circumstances. Soolantra likewise has restrictions on where it should be applied and is not for oral, ophthalmic or intravaginal use. These are label-specific matters: a generic statement that both products are “gentle” is less useful than reviewing the actual instructions for the exact dispensed item.
If a product causes significant or persistent irritation or a suspected allergic reaction, seek advice from the prescribing clinician or pharmacist rather than assuming the reaction is normal or adding another medicine on your own. The broader distinction between prescription ivermectin cream and other formulations is discussed at ivermectin cream 1%. That product category must also be kept separate from ivermectin lotion 0.5% for head lice, which is a different OTC medicine with a different intended use.
A comparison is most relevant when the diagnosis involves inflammatory papules or pustules of rosacea. Persistent diffuse redness without inflammatory lesions, visible facial vessels, episodic flushing and ocular symptoms raise different clinical questions. Even among patients with inflammatory lesions, individual history matters: prior prescription response, skin sensitivity, associated conditions and treatment goals can affect the choice between a cream, gel or foam. The presence of facial bumps alone does not reliably distinguish rosacea from ordinary acne, perioral dermatitis or another skin condition.
For this reason, a brand-versus-alternative shopping question should begin with product identity and indication, not with a self-selected treatment regimen. Soolantra is not FDA-approved for ordinary acne, and the rosacea indication for azelaic acid 15% gel or foam should not be broadened to imply that it addresses every kind of facial inflammation. Conversely, the FDA-labeled indication for Azelex 20% cream concerns acne, even though an individual clinician may assess other circumstances separately.
Readers looking into the relationship between ivermectin and rosacea can use the ivermectin and rosacea overview for disease-context information. This comparison instead concentrates on the choice between identified prescription products. Decisions to switch, stop, combine or add treatment should be made with a clinician who can distinguish the actual clinical target from a search term or product marketing claim.
Soolantra cream 1%, azelaic acid 15% gel and azelaic acid 15% foam are prescription medicines in their U.S. rosacea-labeled forms. A licensed pharmacy needs an appropriate prescription before dispensing these products. The product dispensed should be identified by its active ingredient, strength, vehicle, prescribing directions and packaging label. Generic options may be available for certain prescription products, but approval records or a familiar brand name do not establish the availability of a specific package at a given pharmacy.
The commercial questions differ between ingredients. For Soolantra-specific acquisition, the guide to obtaining Soolantra through a licensed U.S. pharmacy covers the brand-prescription journey. If a pharmacist offers an FDA-approved generic ivermectin cream, that is a same-ingredient brand-to-generic question, not a switch to azelaic acid. An azelaic acid gel or foam is not a generic of Soolantra, so exchanging one active ingredient for the other is a clinical treatment decision rather than routine brand-to-generic substitution.
If the prescribed azelaic acid product is unavailable, clarify whether the alternative is another approved equivalent product of the same formulation, a different vehicle, or an entirely different prescription treatment. The pharmacist may need to contact the prescriber before changing a strength, formulation or drug. Before relying on an internet seller, also verify the legitimacy of the U.S. pharmacy and the requirement for a valid prescription. The essential precautions apply to all prescription topical medicines: no unnamed seller should be treated as a verified stockist without evidence.
Price comparisons are meaningful only when the products are identified correctly. Branded Soolantra cream and an azelaic acid 15% gel are different medicines; a tube and a foam canister are different packaging formats. Pharmacy quotes can depend on the exact product, quantity, brand or generic status, insurance formulary rules, deductible stage and payment method. A lower-looking advertised amount may not correspond to the same labeled formulation or the amount specified by the prescription. No general article can promise coverage, a discount or current local stock.
The evergreen cost framework for the ivermectin brand is covered at Soolantra price and cost factors, while the plan-specific verification process belongs to Soolantra insurance coverage. Here, the practical goal is to compare an appropriately prescribed Soolantra product with an appropriately prescribed azelaic acid product, rather than to imply that a switch should be made solely to reduce out-of-pocket cost. Ask the pharmacy to clarify what product a quote actually identifies and ask the prescriber before changing the drug or vehicle.
The following questions are intended for a clinical or pharmacy conversation, not for choosing a regimen independently. They encourage exact-label comparison and clear distinctions between evidence, patient circumstances, prescription terms and cost. If a quote, prior authorization decision or an online advertisement conflicts with the product specified by the clinician, resolve the mismatch before obtaining or using the medicine.
| Question | What to verify | Why it matters |
|---|---|---|
| Which symptom is the treatment target? | Inflammatory papules and pustules versus persistent redness, flushing, ocular findings or a different diagnosis | The labeled rosacea evidence does not encompass every symptom |
| Which azelaic acid formulation? | Prescription 15% gel, 15% foam, 20% acne cream or a cosmetic preparation | Different vehicles and product categories should not be conflated |
| What does each FDA label cover? | Soolantra inflammatory rosacea lesions; 15% azelaic acid gel/foam inflammatory papules and pustules | Prevents applying an approval claim to an unapproved use |
| What evidence is being compared? | Direct trials, long-term extensions or network meta-analyses; formulations and outcomes used | Study design affects the strength of conclusions |
| Any past sensitivity or adverse response? | Previously irritating vehicles or ingredients, tolerability history and label precautions | Treatment fit is not predictable from percentages |
| Is a change of active drug proposed? | Whether the prescriber authorized ivermectin versus azelaic acid rather than a generic substitution | Different active ingredients are not automatic pharmacy substitutes |
| What is the precise prescription product? | Active ingredient, strength, vehicle, brand or generic, quantity and pharmacy record | Avoids comparing unlike products or packaging |
| What are the cost and coverage conditions? | Exact quoted product, cash versus insurance billing, any required plan review | Avoids reliance on stale or noncomparable quotes |
| When and how will response be reviewed? | Prescriber-directed assessment of response, tolerability and need for reassessment | Neither ingredient guarantees an individual outcome |
No. Soolantra contains ivermectin 1% in a prescription cream. Azelaic acid is a different active ingredient available in several topical forms. A change between the two is not the same as dispensing a generic version of Soolantra.
Yes. U.S. azelaic acid 15% prescription gel products are labeled for inflammatory papules and pustules of mild-to-moderate rosacea. The label should be checked for the exact product rather than assuming every azelaic acid formulation has the same indication.
Yes. Prescription azelaic acid 15% foam has a U.S. indication for inflammatory papules and pustules of mild-to-moderate rosacea. It is a distinct vehicle with its own instructions and precautions, including aerosol flammability warnings.
The U.S. Azelex 20% cream label specifies mild-to-moderate inflammatory acne vulgaris, not an FDA-approved rosacea indication. A clinician may evaluate other uses individually, but the acne label should not be presented as rosacea approval.
Do not assume so. A cosmetic azelaic acid serum is not automatically an FDA-approved rosacea drug or therapeutically equivalent to a prescription cream. Discuss the diagnosis and exact product with a clinician before replacing a prescribed treatment.
No universal superiority claim is supported. Studies vary in their designs, compared formulations and outcome measures. The best-supported comparison concerns particular inflammatory lesions, not every form of redness, flushing or ocular symptoms.
No. The percentages describe amounts of different active ingredients in different vehicles. They are not directly comparable potency scales and should not be used to select a treatment independently.
Soolantra cream 1%, azelaic acid 15% prescription gel and azelaic acid 15% prescription foam require prescriptions. Nonprescription skin-care products containing azelaic acid are a separate category and should not be confused with these medicines.
Local burning, stinging, itching, dryness or irritation can occur with topical products, with details differing by formulation. Azelaic acid foam also carries aerosol-specific precautions. A clinician or pharmacist can review the exact product label and a patient’s skin-sensitivity history.
They contain different active ingredients, so switching between them is not routine brand-to-generic substitution. Any change must be consistent with the prescription and applicable rules and may require the prescriber to authorize a different medicine.